We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+63.05%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$494M
AUM Growth
+$147M
Cap. Flow
+$3.52M
Cap. Flow %
0.71%
Top 10 Hldgs %
82.27%
Holding
60
New
21
Increased
11
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$12M
2
AKTS
Aktis Oncology
AKTS
+$9.1M
3
VIR icon
Vir Biotechnology
VIR
+$7.57M
4
ELVN icon
Enliven Therapeutics
ELVN
+$7.19M
5
DXCM icon
DexCom
DXCM
+$6.27M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$10.4M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.35M
3
MCK icon
McKesson
MCK
+$7.81M
4
A icon
Agilent Technologies
A
+$5.65M
5
PFE icon
Pfizer
PFE
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 99.29%
2 Consumer Staples 0.54%
3 Consumer Discretionary 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.92B
$177M 35.76%
2,104,184
– –
CGON icon
2
CG Oncology
CGON
$6.59B
$87.2M 17.67%
1,288,948
-183,751
-12% -$10.4M
ORKA
3
Oruka Therapeutics
ORKA
$6.03B
$37.3M 7.55%
760,424
+100,000
+15% +$3.48M
CATX icon
4
Perspective Therapeutics
CATX
$355M
$25.2M 5.11%
6,049,999
+2,839,266
+88% +$12M
JBIO
5
Jade Biosciences
JBIO
$1.33B
$19.7M 3.99%
1,400,708
– –
ELVN icon
6
Enliven Therapeutics
ELVN
$4.24B
$15.7M 3.18%
400,000
+259,700
+185% +$7.19M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$42.5B
$13.6M 2.75%
450,100
+32,800
+8% +$1.06M
CNTX icon
8
Context Therapeutics
CNTX
$35.3M
$13.1M 2.65%
4,998,267
-506,588
-9% -$1.18M
RGEN icon
9
Repligen
RGEN
$9.95B
$9.17M 1.86%
77,800
+27,500
+55% +$3.84M
PVLA
10
Palvella Therapeutics
PVLA
$2.16B
$8.73M 1.77%
70,000
+50,700
+263% +$5.29M
MDT icon
11
Medtronic
MDT
$117B
$8.66M 1.75%
100,000
-7,600
-7% -$728K
VIR icon
12
Vir Biotechnology
VIR
$1.83B
$8.51M 1.72%
+950,000
New +$7.57M
AKTS
13
Aktis Oncology
AKTS
$1.43B
$8.38M 1.7%
+468,566
New +$9.1M
IMUX icon
14
Immunic
IMUX
$210M
$7.44M 1.51%
669,941
+200,000
+43% +$1.79M
DXCM icon
15
DexCom
DXCM
$34.3B
$5.65M 1.14%
+90,000
New +$6.27M
EHC icon
16
Encompass Health
EHC
$11.9B
$4.06M 0.82%
42,000
+10,400
+33% +$1.07M
BSX icon
17
Boston Scientific
BSX
$67.9B
$3.77M 0.76%
60,000
-54,500
-48% -$4.36M
TENX icon
18
Tenax Therapeutics
TENX
$79.7M
$3.45M 0.7%
+215,934
New +$2.92M
GILD icon
19
Gilead Sciences
GILD
$181B
$2.79M 0.56%
+20,000
New +$2.8M
PHAT icon
20
Phathom Pharmaceuticals
PHAT
$743M
$2.77M 0.56%
249,390
+43,314
+21% +$547K
KPTI icon
21
Karyopharm Therapeutics
KPTI
$42.4M
$2.58M 0.52%
463,741
+329,175
+245% +$2.51M
CNC icon
22
Centene
CNC
$32B
$2.29M 0.46%
70,000
-49,400
-41% -$2.03M
MSLE
23
Satellos Bioscience
MSLE
$184M
$2.18M 0.44%
+387,769
New +$3.81M
SCYX icon
24
SCYNEXIS
SCYX
$53.6M
$1.91M 0.39%
260,208
– –
NTRA icon
25
Natera
NTRA
$47B
$1.8M 0.36%
9,000
-2,800
-24% -$603K
1
2 3

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q1 2026 Portfolio in Review

As of Q1 2026, Avidity Partners Management held 60 positions worth $494M, up 42% from $347M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Avidity Partners Management's Q1 2026 filing shows 21 new, 11 increased, 10 reduced and 15 closed positions. Its largest new stake was Aktis Oncology: 468,566 shares worth $8.38M. The largest sale was CG Oncology, an estimated $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Avidity Partners Management's largest Q1 2026 buy was Aktis Oncology: 468,566 shares worth $8.38M.
  • Avidity Partners Management added most to Perspective Therapeutics in Q1 2026, an estimated $12M increase.
  • Avidity Partners Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $10.4M.
  • Avidity Partners Management fully exited Alnylam Pharmaceuticals in Q1 2026, selling an estimated $8.35M.
  • Avidity Partners Management's ten largest holdings make up 82% of its $494M portfolio in Q1 2026.
  • Avidity Partners Management opened 21 new positions and closed 15 in Q1 2026.
  • Avidity Partners Management's portfolio value rose 42% quarter-over-quarter to $494M.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.